ACCC COVID-19 Resource Center & Discussion Group
for Insights on Providing Optimal Patient Care During the Pandemic.
Providing a VOICE for Texas' MULTIDISCIPLINARY CANCER CARE TEAMS and the PATIENTS THEY SERVE since 1988
Meetings & Education
Articles and Blogs
Fellows Abstract Competition
Patient Advocacy Organizations
State & Federal Resources
Find A Clinical Trial
Off-Label Use Literature
National Professional Organizations
TxSCO Corporate Members
Become a Corporate Member
Industry News Archive
COVID-19 Featured Resources
FDA Approves Nivolumab Plus Ipilimumab for Metastatic Colorectal Cancer
On July 11, the Food and Drug Administration (FDA) approved nivolumab (Opdivo, Bristol-Myers Squibb) plus Yervoy (ipilimumab, Bristol-Myers Squibb) for the treatment of adult and pediatric patients 12 years and older with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.
Read the full Bristol-Myers Squibb press release here.